<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03203733</url>
  </required_header>
  <id_info>
    <org_study_id>BraincoolUppsalaU</org_study_id>
    <nct_id>NCT03203733</nct_id>
  </id_info>
  <brief_title>Cryoprotection of Chemotherapy-induced Oral Mucositis After Autologous Stem Cell Transplantation, a Randomized Study</brief_title>
  <official_title>Cryoprotection of Chemotherapy-induced Oral Mucositis After Autologous Stem Cell Transplantation, a Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates, among study patients with lymphoma or myeloma undergoing autologous&#xD;
      SCT, whether cooling oral mucosa with a cooling device compared with ice cubes/crushed ice or&#xD;
      ice pop succeeds in reducing the degree of oral mucositis (OM) according to the Oral&#xD;
      Mucositis Assessment Scale (OMAS) total,degree of OM according to World Health Organisation&#xD;
      (WHO), tolerability of either cooling method. The study is also aiming to , patients&#xD;
      subjective experience of OM, rating of general quality of life and oral pain, number of days&#xD;
      with total parenteral nutrition (TPN), number of hospital days, total dose of opioids, and C&#xD;
      reactive protein during time in care.&#xD;
&#xD;
      Finally, the study aims to evaluate weight loss, Leukocyte particle concentration, number of&#xD;
      days until bone marrow response, S-albumin, and body temperature.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The degree of OM is assessed at eight intraoral locations, in accordance with the Oral&#xD;
      Mucositis Assessment Scale (OMAS) (graded 0-3 for ulceration and 0-2 for erythema). 0&#xD;
      corresponds to &quot;normal&quot; while 3 and 2 are &quot;sore &gt;3 cm2&quot; and &quot;severe erythema&quot; respectively.&#xD;
      The assessment generates both an average for OMAS ulceration (0-3) and OMAS erythema (0-2)&#xD;
      and a total average OMAS (0-5), which is the mean of both ulceration and erythema.&#xD;
&#xD;
      Besides OMAS, ulceration and erythema are also assessed with the WHO scale (graded 0-4) where&#xD;
      0 is &quot;no mucositis&quot; and 4 is &quot;ulceration, total parenteral nutrition&quot;.&#xD;
&#xD;
      Assessment with OMAS and WHO is done by a dentist, blinded to treatment group, three times a&#xD;
      week, for example, Monday, Wednesday, Friday, until discharge or at most day +28.Assessment&#xD;
      with the WHO is also performed by nurses who are not blinded to the treatment group, three&#xD;
      times a week.&#xD;
&#xD;
      Furthermore, the patients, after cooling ends, assess the tolerability of the respective&#xD;
      cooling method with the aid of a questionnaire developed for the study. The questionnaire is&#xD;
      intended to give some idea of any discomfort or side effects the patients feel as a result of&#xD;
      the cooling method.&#xD;
&#xD;
      The patients assess their perception of oral problems daily with the aid of specific&#xD;
      questions in a diary developed for the study. The questions are intended to give a picture of&#xD;
      the effect of OM on the patient's general status.&#xD;
&#xD;
      General quality of life is assessed twice during the study period, before the start of&#xD;
      treatment and at discharge, with a validated quality of life instrument.&#xD;
&#xD;
      Oral pain is assessed with a visual analog scale (VAS) with the extremes graded on a&#xD;
      10-figure scale (0-10) where 0 is &quot;no pain&quot; and 10 is &quot;unbearable pain&quot;.&#xD;
&#xD;
      Information about total parenteral nutrition (TPN), number of hospital days, total dose of&#xD;
      opioids, weight loss, and body temperature will be retrieved from patient records. Laboratory&#xD;
      results of blood tests will be retrieved from each department's register of test results.&#xD;
&#xD;
      The result of the assessments is documented on sheets for the purpose in a patient's&#xD;
      individual kardex.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 6, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OM according to OMAS total during 28 days or until discharge</measure>
    <time_frame>28 days or until discharge</time_frame>
    <description>Assesment with OMAS is done by a dentist blinded to treatment group, three times a week during 28 days or until discharge. Assessment with the not blinded to the treatment group, three times a week during 28 days or until discharge.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Cryotherapy Effect</condition>
  <arm_group>
    <arm_group_label>'Cooral™'</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral cooling with use of cooling device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cryotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cryoterapy consists of ice cubes or crossed ice and used as standard treatment for oral cooling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cooral™</intervention_name>
    <description>An intraoral cooling device which is as effective as ice but with better patient comfort. The cooling device has the advantage that the water temperature can be modified. It enables that the unacceptable low temperatures that occur with ice cooling can be avoided.</description>
    <arm_group_label>'Cooral™'</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cryotherapy</intervention_name>
    <description>Oral cooling by ice chips or crushed ice or ice pop</description>
    <arm_group_label>cryotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 16 and 99 years of age diagnosed with lymphoma or myeloma&#xD;
&#xD;
          -  Able to communicate in Swedish&#xD;
&#xD;
          -  Treated with bis-chloroethylnitrosourea, etoposide, cytarabine, and&#xD;
             cyclophosphamide(BEAC) or bis-chloroethylnitrosourea, etoposide, cytarabine, and&#xD;
             melphalan (BEAM) (lymphoma diagnosis), melphalan (myeloma diagnosis), before stem cell&#xD;
             transplantation (SCT)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not understand oral and written information in Swedish.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karin Garming Legert, Dentist, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section for Orofacial diagnosis and surgery, Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mats Jontell, dentist</last_name>
    <role>Study Director</role>
    <affiliation>Oral Medicine Clinic, Department of Odontology, University of Gothenburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Torbjörn Karlsson, MD physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section for Hematology &amp; Coagulation, Uppsala University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PA Broliden, MD, PhD,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology Center, M54, Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franz Rommel, physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section for Hematology, Linköping University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erik Ahlstrand, physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section for Hematology, Örebro University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rikshospitalet in Oslo</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Peterson DE, Bensadoun RJ, Roila F; ESMO Guidelines Working Group. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol. 2011 Sep;22 Suppl 6:vi78-84. doi: 10.1093/annonc/mdr391. Erratum in: Ann Oncol. 2012 Mar;23(3):810.</citation>
    <PMID>21908510</PMID>
  </reference>
  <reference>
    <citation>Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014 May 15;120(10):1453-61. doi: 10.1002/cncr.28592. Epub 2014 Feb 25. Review. Erratum in: Cancer. 2015 Apr 15;121(8):1339.</citation>
    <PMID>24615748</PMID>
  </reference>
  <reference>
    <citation>Elting LS, Keefe DM, Sonis ST, Garden AS, Spijkervet FK, Barasch A, Tishler RB, Canty TP, Kudrimoti MK, Vera-Llonch M; Burden of Illness Head and Neck Writing Committee. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008 Nov 15;113(10):2704-13. doi: 10.1002/cncr.23898.</citation>
    <PMID>18973181</PMID>
  </reference>
  <reference>
    <citation>Naidu MU, Ramana GV, Rani PU, Mohan IK, Suman A, Roy P. Chemotherapy-induced and/or radiation therapy-induced oral mucositis--complicating the treatment of cancer. Neoplasia. 2004 Sep-Oct;6(5):423-31. Review.</citation>
    <PMID>15548350</PMID>
  </reference>
  <reference>
    <citation>Legert KG, Remberger M, Ringdén O, Heimdahl A, Dahllöf G. Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients. Support Care Cancer. 2014 Aug;22(8):2133-40. doi: 10.1007/s00520-014-2190-7. Epub 2014 Mar 20.</citation>
    <PMID>24647488</PMID>
  </reference>
  <reference>
    <citation>Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST; Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004 May 1;100(9 Suppl):2026-46.</citation>
    <PMID>15108223</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral Mucositis , cooling, cryotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

